Evidence map›Paper›PMID 33845800›Full record

SynthesisBMC cancer2021

Bioinformatics analysis of the expression and role of microRNA-221-3p in head and neck squamous cell carcinoma.

Ziyan Zhou, Wenling Wu, Jixi Li, Chang Liu, Zixi Xiao, Qinqiao Lai, Rongxing Qin, Mingjun Shen, Shuo Shi, Min Kang

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Analysis of the differences in immune-related genes and immune cell subtypes in acute myocardial infarction.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Ziyan Zhou *Department of Radiation Oncology, Guangxi Medical University First Affiliated Hospital, Nanning, 530021, Guangxi, People's Republic of China.
Wenling Wu *Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China.
Jixi LiDepartment of Radiation Oncology, Guangxi Medical University First Affiliated Hospital, Nanning, 530021, Guangxi, People's Republic of China.
Chang LiuGuangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China.
Zixi XiaoGuangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China.
Qinqiao LaiGuangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China.
Rongxing QinGuangxi Medical University, Nanning, 530021, Guangxi, People's Republic of China.
Mingjun ShenDepartment of Radiation Oncology, Guangxi Medical University First Affiliated Hospital, Nanning, 530021, Guangxi, People's Republic of China.
Shuo ShiDepartment of Thoracic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Min KangDepartment of Radiation Oncology, Guangxi Medical University First Affiliated Hospital, Nanning, 530021, Guangxi, People's Republic of China. kangmin@gxmu.edu.cn.ORCID http://orcid.org/0000-0003-2287-8757
Guangxi Medical University · CN

Funding

Guangxi Zhuang Region Health Department (CN) No.S2018087National Natural Science Foundation of China No. 81460460,81760542Science and Technology Major Project of Guangxi No. 2016GXNSFAA380252, 2018AB61001 and 2014GXNSFBA118114
6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, associated with a high rate of morbidity and mortality. However, the target genes of miR-221-3p and the underlying mechanism involved in HNSCC are still not clear. Therefore, in the current study, we studied the role of miR-221-3p in the HNSCC.

methodsTissues collected from 48 control and 21 HNSCC patients were processed to check the differential expression of miR-221-3p by RT-qPCR. Overexpression of microRNA-221-3p (miR-221-3p) is significantly correlated to the onset and progression of HNSCC. We also conducted the meta-analysis of the cancer literature from the cancer genome atlas (TCGA) and the Gene Expression Omnibus (GEO) database to estimate the expression of miR-221-3p in HNSCC. The miR-221-3p target genes in the HNSCC were predicted with the miRWalk and TCGA databases, and functionally annotated via the Gene Ontology. Finally, Spearman's analysis was used to determine the role of the related target genes in important pathways involved in the development of HNSCC.

resultsWe observed a significantly higher expression of miR-221-3p in HNSCC compared to the normal with a summary receiver operating characteristic (sROC) of 0.86(95% Cl: 0.83,0.89). The KEGG and GO comprehensive analysis predicted that miR-221-3p might be involved in the development of HNSCC through the following metabolic pathways, viz. Drug metabolism - cytochrome P450 UGT1A7 and MAOB may be important genes for the role of miR-221-3p.

conclusionBased on bioinformatics analysis, our results indicate that miR-221-3p may be used as a non-invasive and hypersensitive biomarker in the diagnosis. Thus, it can be concluded that miR-221-3p may be an extremely important gene locus involved in the process of the deterioration and eventual tumorigenesis of HNSCC. Hopefully, additional work will validate its usefulness as a target for future clinical research.

Indexed as

Computational BiologyGene Expression Regulation, NeoplasticAdultAgedBiomarkers, TumorFemaleGene Expression ProfilingGene OntologyGene Regulatory NetworksHumansMaleMicroRNAsMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisBiomarkers, TumorMicroRNAsMIR221, humanBioinformaticsHNSCCmiR-221-3pRT-qPCRTCGA

Identifiers

PMID33845800
PMCPMC8042693
OpenAlexW3112671471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.